Lexeo Therapeutics, Inc. Common Stock
LXEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | -0.98 | -0.25 | -0.01 |
| FCF Yield | -39.03% | -16.68% | -21.93% | -17.54% |
| EV / EBITDA | -1.91 | -3.72 | -3.26 | -2.31 |
| Quality | ||||
| ROIC | -81.71% | -54.73% | -67.39% | -39.13% |
| Gross Margin | 0.00% | 0.00% | -75.08% | 99.19% |
| Cash Conversion Ratio | 0.83 | 0.90 | 0.92 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 8.05% | 1,183,234.44% |
| Free Cash Flow Growth | -36.83% | -7.57% | -25.00% | -1,316.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 1.65 | 1.10 | 2.68 |
| Interest Coverage | -927.77 | -334.21 | -664.93 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,169.93 | -751.39 | -853.69 | -83,346.89 |